Faculty Opinions recommendation of Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study.

Author(s):  
Philip Rosenthal
2013 ◽  
Vol 58 (5) ◽  
pp. 922-927 ◽  
Author(s):  
Pablo Bellot ◽  
Martin-Walter Welker ◽  
German Soriano ◽  
Markus von Schaewen ◽  
Beate Appenrodt ◽  
...  

2015 ◽  
Vol 400 (8) ◽  
pp. 979-983 ◽  
Author(s):  
M. N. Thomas ◽  
G. H. Sauter ◽  
A. L. Gerbes ◽  
M. Stangl ◽  
T. S. Schiergens ◽  
...  

2014 ◽  
Vol 60 (1) ◽  
pp. S244 ◽  
Author(s):  
A. De Gottardi ◽  
V. Banz ◽  
F. Storni ◽  
G. Stirnimann ◽  
N. Semmo ◽  
...  

2017 ◽  
Vol 46 (3) ◽  
pp. 1138-1145 ◽  
Author(s):  
Ruihong Zhao ◽  
Juan Lu ◽  
Yu Shi ◽  
Hong Zhao ◽  
Kaijin Xu ◽  
...  

Liver cirrhosis is a health problem worldwide, and ascites is its principal symptom. Refractory ascites is intractable and occurs in 5%–10% of all patients with ascites due to cirrhosis. Refractory ascites leads to a poor quality of life and high mortality rate. Ascites develops as a result of portal hypertension, which leads to water–sodium retention and renal failure. Various therapeutic measures can be used for refractory ascites, including large-volume paracentesis, transjugular intrahepatic portosystemic shunt, vasoconstrictive drugs, and an automated low-flow ascites pump system. However, ascites generally can be resolved only by liver transplantation. Because not all patients can undergo liver transplantation, traditional approaches are still used to treat refractory ascites. The choice of treatment modality for refractory ascites depends, among other factors, on the condition of the patient.


2017 ◽  
Vol 10 (2) ◽  
pp. 283-292 ◽  
Author(s):  
Guido Stirnimann ◽  
Vanessa Banz ◽  
Federico Storni ◽  
Andrea De Gottardi

Cirrhotic patients with refractory ascites (RA) can be treated with repeated large volume paracentesis (LVP), with the insertion of a transjugular intrahepatic portosystemic shunt (TIPS) or with liver transplantation. However, side effects and complications of these therapeutic options, as well as organ shortage, warrant the development of novel treatments. The automated low-flow ascites pump (alfapump®) is a subcutaneously-implanted novel battery-driven device that pumps ascitic fluid from the peritoneal cavity into the urinary bladder. Ascites can therefore be aspirated in a time- and volume-controlled mode and evacuated by urination. Here we review the currently available data about patient selection, efficacy and safety of the alfapump and provide recommendations for the management of patients treated with this new method.


2019 ◽  
Vol 50 (9) ◽  
pp. 978-987 ◽  
Author(s):  
Antonia Lepida ◽  
Astrid Marot ◽  
Eric Trépo ◽  
Delphine Degré ◽  
Christophe Moreno ◽  
...  

2017 ◽  
Vol 3 (4) ◽  
pp. 20170025 ◽  
Author(s):  
Salil Karkhanis ◽  
Robert Jones ◽  
Andrew Willis ◽  
Eoghan Mccarthy ◽  
Zergham Zia ◽  
...  

2017 ◽  
Vol 35 (4) ◽  
pp. 402-410 ◽  
Author(s):  
Elisa Pose ◽  
Andres Cardenas

Ascites is the most common complication associated with cirrhosis resulting in poor quality of life, high risk of development of other complications of cirrhosis, increased morbidity and mortality associated with surgical interventions, and poor long-term outcome. Patients with cirrhosis and a first onset of ascites, have a probability of survival of 85% during the first year and 56% at 5 years without liver transplantation. Ascites is caused due to increased renal sodium retention as a result of increased activity of the renin-angiotensin-aldosterone system in response to marked vasodilation of the splanchnic circulation. The practical management of ascites involves the proper evaluation of a patient with a thorough history and physical exam. In addition, complete laboratory, ascitic fluid, and radiological tests should be performed. One of the most important steps in the initial assessment of patients with ascites is to refer the appropriate candidates for liver transplantation, as it offers a definitive cure for cirrhosis and its complications. While the initial management of uncomplicated ascites with low sodium diet and diuretic treatment is straightforward in a majority of patients, approximately 10% of patients fail to respond to diuretics and become a real therapeutic challenge. The initial treatment of choice in patients with refractory ascites is large-volume paracentesis (LVP) associated with intravenous albumin; some patients also benefit from transjugular intrahepatic portosystemic shunts (TIPS). When repeated LVP or TIPS cannot be performed, other approaches using vasoconstrictors such as midodrine can be considered although data are scarce. A newly designed automated low flow pump system (Alfapump), which is designed to move ascites from the peritoneal cavity to the urinary bladder where it is eliminated spontaneously through diuresis is promising, but the data are also limited and safety is still a matter of concern. This article focuses on the practical aspects of the evaluation and treatment of patients with ascites and cirrhosis and also discusses how to translate our current understanding of ascites pathophysiology into new treatment methods for patients with fluid retention.


Sign in / Sign up

Export Citation Format

Share Document